Lilly is upping its bet on Alzheimer's. The Indianapolis-based drug maker announced it has licensed experimental tracers that can hone in on and mark tau tangles that are believed to be a cause of the brain-degenerating disease.
February 11, 2013
The Food and Drug Administration issued draft guidance Thursday on clinical trials for early-stage Alzheimer's drugs.
A new test that measures amyloid levels in the spinal fluid of people with mild cognitive impairment could help physicians more accurately predict who will develop Alzheimer's, a new study finds.
